Synovial Sarcoma Survival

In the U.S.

Prediction Tools: DisclaimerThe prediction tools, also known as prognostic nomograms, located on the MSK Web site are for general health information only. The prediction tools are not to be used as a substitute for medical advice, diagnosis, or treatment of any health condition or problem.Users of the prediction tools should not rely on information provided by the prediction tools for their own health problems. Questions should be addressed to your own physician or other healthcare provider.MSK makes no warranties, nor express or implied representations whatsoever, regarding the accuracy, completeness, timeliness, comparative or controversial nature, or usefulness of any information contained or referenced in the prediction tools. MSK does not assume any risk whatsoever for your use of the prediction tools or the information contained herein. Health related information changes frequently and therefore information contained in the prediction tools may be outdated, incomplete or incorrect.Use of the prediction tools does not create an express or implied physician-patient relationship. MSK does not endorse or claim validity for the prediction tools found on the MSK Web site. The activities and products of MSK and its developers and agents (collectively MSK) are not endorsed by our past, present, or future employers. MSK does not record specific prediction tool user information and does not contact users of the prediction tools.You are hereby advised to consult with a physician or other professional healthcare provider prior to making any decisions, or undertaking any actions or not undertaking any actions related to any healthcare problem or issue you might have at any time, now or in the future. In using the prediction tools, you agree that neither MSK nor any other party is or will be liable or otherwise responsible for any decision made or any action taken or any action not taken due to your use of any information presented in the prediction tools.

Our synovial sarcoma nomogram is a tool designed to predict the likelihood of surviving three years and five years after being diagnosed with synovial sarcoma, based on clinical and pathologic factors known before surgery. This tool is not designed for patients who received chemotherapy with anthracycline and ifosfamide (AI) before or shortly after surgery, as the nomogram predictions may be inaccurate.

Results produced by this tool are based on data from patients treated at MSK, a large research institution with surgeons who perform a high volume of synovial sarcoma procedures. All results must be understood in the context of each patient’s specific treatment plan. Patients and caregivers using this tool should discuss the result with the patient’s physician.

To gather the information required to use this nomogram, use our worksheet.

Enter Your Information

All fields are required unless noted optional

Where is the tumor located?

Note: A tumor is considered to be in the upper extremity if it is in the hand, arm, or shoulder joint, and it is considered to be in the lower extremity if it is in the foot, leg, or groin.

What is the largest diameter of the primary tumor? cm (1 to 30)

What is the depth of the tumor?

Note: The depth of the tumor is categorized as either superficial or deep relative to the investing fascia. Depth is considered deep if it involves the superficial fascia or involves underlying muscle.

What is fascia?: Fascia refers to a sheet of connective tissue surrounding and binding together body structures, such as muscles, blood vessels, and nerves. The superficial fascia lies under the skin and superficial fat layers, and it surrounds and binds together the underlying muscles.

What is the histologic variant (subtype) of the tumor?

What is histology?: Histology refers to the exact type of cancer based on examination of the tumor tissue under the microscope. Synovial sarcoma is classified as Biphasic; Monophasic; or Poorly Differentiated.

Clear

Supporting Publications

Synovial Sarcoma Survival

Probability of survival at three years and five years after being diagnosed with synovial sarcoma

Canter RJ, Qin LX, Maki RG, Brennan MF, Ladanyi M, Singer S. A synovial sarcoma-specific preoperative nomogram supports a survival benefit to ifosfamide-based chemotherapy and improves risk stratification for patients. Clin Cancer Res. 2008 Dec 15;14(24):8191-7. doi: 10.1158/1078-0432.CCR-08-0843. PMID: 19088035; PMCID: PMC2779709.

Changing how the world understands and treats cancer

Training the next generation of clinicians and scientists

We’re here for you.

Make an appointment

Speak to a care advisor

We treat every type of cancer, including the most important one: yours.

Partner with us to treat your patient’s cancer.

CALL OUR DEDICATED CLINICIAN ACCESS NUMBER

Our mission: Ending cancer for life.

In the U.S.

Outside of the U.S.

Enter Your Information

Supporting Publications

Synovial Sarcoma Survival